Related Experiment Videos
Distribution of cyclooxygenase isoforms in murine chronic granulomatous inflammation. Implications for future
I Appleton1, A Tomlinson, J A Mitchell
1Department of Experimental Pathology, William Harvey Research Institute, St. Bartholomew's Hospital Medical College, London, U.K.
Abstract:
Inhibition of the enzyme cyclooxygenase (COX) is the basis for the mechanism of action of non-steroidal anti-inflammatory drugs (NSAIDs). COX exists as a constitutive (COX-1) and a mitogen-inducible (COX-2) isoform. The relative contribution of COX-1 and COX-2 to inflammation is unknown. This study investigated COX activity and the distribution of COX-1 and COX-2 during the development of a murine air pouch model of chronic granulomatous inflammation. COX activity progressively rose and was maximal at day 14. Of the COX metabolites measured, PGE2 was the greatest > 6-keto PGF1a > TXB2 > PGF2a. By day 7, COX-2-labelled fibroblast- and macrophage-like cells were observed and their number and distribution increased with time. At all time points, endothelial cells of venules in the loose connective tissue of the dermis showed immunoreactivity for COX-2. After day 14, labelling of capillaries in the granuloma was also observed. This study is the first to show that COX-2 is the predominant COX isoform in all stages of the inflammatory response. These results suggest that selective inhibition of COX-2 may prove more beneficial, with fewer gastric and renal side-effects, than existing NSAID therapy for the treatment of chronic inflammatory diseases.
Insights
This study reveals cyclooxygenase-2 (COX-2) is the primary enzyme in chronic inflammation. Selective COX-2 inhibition may offer safer non-steroidal anti-inflammatory drug (NSAID) treatments for inflammatory diseases.
Area of Science:
- Biomedical Science
- Inflammation Research
- Pharmacology
Background:
- Non-steroidal anti-inflammatory drugs (NSAIDs) function by inhibiting cyclooxygenase (COX) enzymes.
- Two main isoforms exist: COX-1 (constitutive) and COX-2 (mitogen-inducible).
- The specific roles of COX-1 and COX-2 in inflammation remain unclear.
Purpose of the Study:
- To investigate cyclooxygenase (COX) activity and the distribution of COX-1 and COX-2 isoforms.
- To understand their roles during the development of chronic granulomatous inflammation.
- To evaluate the potential for selective COX-2 inhibition in treating inflammatory diseases.
Main Methods:
- Utilized a murine air pouch model to study chronic granulomatous inflammation.
- Measured COX activity and quantified COX metabolite levels (PGE2, 6-keto PGF1a, TXB2, PGF2a).
- Employed immunohistochemistry to map the distribution of COX-1 and COX-2 in inflammatory tissues over time.
Main Results:
- COX activity increased progressively, peaking at day 14.
- Prostaglandin E2 (PGE2) was the most abundant COX metabolite.
- COX-2 expression was detected in fibroblast- and macrophage-like cells, increasing with inflammation.
- Endothelial cells of venules and later capillaries within the granuloma also showed COX-2 immunoreactivity.
Conclusions:
- This research demonstrates COX-2 as the predominant COX isoform throughout all stages of the inflammatory response.
- These findings suggest that targeted inhibition of COX-2 could provide therapeutic benefits.
- Selective COX-2 inhibitors may offer an improved safety profile compared to traditional NSAIDs, with reduced gastric and renal side effects.